Many markers are reportedly expressed specifically on CML LSCs, including CD25, CD26, and interleukin-1 receptor accessory protein (IL-1RAP), which can be used as biomarkers for diagnostic, prognostic, or therapeutic purposes [30–32]. This evidence concerns the gene IL2RA and chronic myelogenous leukemia, BCR-ABL1 positive.